Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: Subgroup analysis of the Alliance A031203 CABOSUN trial Journal Article
| Authors: | George, D. J.; Hessel, C.; Halabi, S.; Michaelson, M. D.; Hahn, O.; Walsh, M.; Picus, J.; Small, E. J.; Dakhil, S.; Feldman, D. R.; Mangeshkar, M.; Scheffold, C.; Morris, M. J.; Choueiri, T. K. |
| Article Title: | Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: Subgroup analysis of the Alliance A031203 CABOSUN trial |
| Abstract: | Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158. © 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. |
| Keywords: | immunohistochemistry; adult; controlled study; protein expression; treatment response; aged; middle aged; major clinical study; overall survival; sunitinib; advanced cancer; cancer risk; drug safety; bone metastasis; nuclear magnetic resonance imaging; follow up; progression free survival; phase 2 clinical trial; randomized controlled trial; retrospective study; cancer therapy; renal cell carcinoma; lung metastasis; visceral metastasis; scatter factor receptor; cabozantinib; human; male; female; priority journal; article |
| Journal Title: | The Oncologist |
| Volume: | 24 |
| Issue: | 11 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-11-01 |
| Start Page: | 1497 |
| End Page: | 1501 |
| Language: | English |
| DOI: | 10.1634/theoncologist.2019-0316 |
| PUBMED: | 31399500 |
| PROVIDER: | scopus |
| PMCID: | PMC6853096 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work